CASR and cancer: In contrast, the CaSR is reported to be epigenetically silenced in several cancers, as described below, and we have previously shown that the epigenetic targeting compound JQ1, which inhibits the bromo and extra terminal domain family of proteins that recognise acetylated histone residues and promote gene transcription, down‐regulates the CaSR in pituitary adenoma cells.13